Edwards Lifesciences (NYSE:EW) Price Target Raised to $105.00

Edwards Lifesciences (NYSE:EW) had its price target increased by Mizuho from $100.00 to $105.00 in a research report sent to investors on Wednesday,Benzinga reports. Mizuho currently has an outperform rating on the medical research company’s stock.

EW has been the topic of several other reports. Evercore reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a report on Monday, July 6th. Robert W. Baird raised their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. TD Cowen reaffirmed a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Truist Financial set a $90.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Finally, Barclays reiterated an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $98.95.

Edwards Lifesciences Trading Down 2.4%

EW stock opened at $85.72 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. Edwards Lifesciences has a 1-year low of $72.30 and a 1-year high of $96.29. The business has a 50 day simple moving average of $87.34 and a two-hundred day simple moving average of $83.94. The company has a market capitalization of $49.36 billion, a price-to-earnings ratio of 45.60, a PEG ratio of 2.20 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Research analysts anticipate that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction on Friday, July 10th. The shares were sold at an average price of $91.70, for a total value of $56,762.30. Following the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,671,117.80. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,577 shares of company stock worth $3,855,527 over the last three months. 0.31% of the stock is owned by insiders.

Institutional Trading of Edwards Lifesciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EW. Norges Bank bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after buying an additional 4,108,270 shares during the period. Viking Global Investors LP bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth approximately $238,688,000. Marshall Wace LLP lifted its stake in shares of Edwards Lifesciences by 66.1% during the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after acquiring an additional 2,359,128 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in Edwards Lifesciences by 132.4% during the 1st quarter. Bank of America Corp DE now owns 3,883,419 shares of the medical research company’s stock valued at $310,984,000 after acquiring an additional 2,212,208 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.